Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ:ENTX) has designed the pivotal study for EB613 as…
Medigus’ Polyrizon Inks Agreement To Develop Therapies For Traumatic Spinal Cord Injuries
Polyrizon Ltd, in which Medigus Ltd (NASDAQ:MDGS) owns a 37.03% stake, signed a binding Collaboration Agreement with NurExone Biologic Inc for therapies for traumatic spinal…
Medigus Announces Polyrizon Signs Binding Collaboration Agreement With NurExone Biologic For Intranasal Administration Of Therapy For Spinal Cord Injuries, Polyrizon Is Entitled For Up to $3.35M Plus Future Royalties; Medigus Owns 37.03% Of Polyrizon
Medigus Ltd. (NASDAQ:MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that Polyrizon Ltd.
Eledon Pharmaceuticals Announces The First Patient Dosed In Phase 1b Trial Evaluating Tegoprubart In Kidney Transplantation
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ:ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell
GSK Completes Spin Off Of Its Consumer Healthcare Business
GSK plc (NYSE:GSK) has completed the demerger of the Consumer Healthcare business to form the Haleon Group. Reuters reported that shares in…
Eton Pharmaceuticals Announces FDA Approval Of ZONISADE
Eton Pharmaceuticals, Inc. (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has
Eliem Announces Updated Development Plans And The Advancement Of ETX-155 For The Treatment Of Major Depressive Disorder
Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023
Sufficient capital expected to fund operations until mid-2024
Regulus Therapeutics Announces On July 12, Sanofi Notified Co. Of Its Decision To Terminate Phase 2 Clinical Study Of Lademirsen For Treatment Of Alport Syndrome
https://www.sec.gov/ix?doc=/Archives/edgar/data/1505512/000119312522194935/d346170d8k.htm
HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On ‘Unclear Path’
The merger agreement between EW Partners and TherapeuticsMD Inc (NASDAQ:TXMD) was terminated, with EW Partners not acquiring the majority of shares…
HC Wainwright Reiterates On Pluristem After Encouraging Initial Data
Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture surgery.